Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical is supported by a differentiated, FDA-cleared LIBERTY platform that directly addresses the two biggest adoption barriers in endovascular robotics: high capital cost and workflow disruption, while also reducing physician radiation exposure by 92% and delivering 100% navigation success with zero device-related adverse events in the pivotal study. Its fully disposable, single-use model at roughly $3,500-$4,000 per procedure creates a recurring-revenue stream with a leaner cost structure than capital-intensive robotic peers, and the addressable U.S. peripheral endovascular market remains large at about 2.5 million annual procedures across roughly 6,000 physicians. With nearly $68 million in cash and no debt, early commercialization is well funded, and the company is already seeing sequential revenue growth from a small but expanding customer base.

Microbot Medical is viewed negatively because it is only beginning to recognize revenue, and those sales depend entirely on the LIBERTY Endovascular Robotic Surgical System, a single product whose commercial success still hinges on manufacturing scale-up, physician adoption, and market acceptance. The company entered market release in April 2026 with no prior revenue history, yet hospitals may be slow to change workflows or absorb the cost of a single-use device without dedicated CMS reimbursement, while expansion into coronary and neurovascular uses would require new regulatory submissions and clinical data. Financially, the setup remains weak: operating expenses are expected to rise from about $15 million in FY25 to $22.5 million in FY26, $28 million in FY27, and $37 million in FY28, with net losses widening to roughly $(22) million, $(24) million, and $(26) million.